Insulin resistance and metabolic syndrome are related to non-alcoholic fatty liver disease, but not visceral adiposity index, in severely obese patients

Revista Espanola de Enfermedades Digestivas

Volumn 106, Issue 8, 2014, Pages 522-528

  Díez Rodríguez, Rubén ^a   Ballesteros Pomar, María Dolores ^a   Calleja Fernández, Alicia ^a   González De Francisco, Tomás ^a   González Herráez, Luis ^a   Calleja Antolín, Sara ^a   Cano Rodríguez, Isidoro ^a   Olcoz Goñi, José Luis ^a  

^a Complejo Asistencial Universitario de León   (Spain)

Author keywords

Abdominal obesity; Fatty liver; Non alcoholic steatohepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; TRIACYLGLYCEROL;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; FEMALE; HEPATITIS; HISTOLOGY; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; PREVALENCE; PROSPECTIVE STUDY; SCORING SYSTEM; VISCERAL ADIPOSITY INDEX; COMPLICATION; CROSS-SECTIONAL STUDY; MIDDLE AGED; MORBID OBESITY;

ADIPOSITY; ADULT; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY, MORBID;

EID: 84928809818     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012;142:1592-609.
2. Ballesteros Pomar M, Urioste Fondo A, González de Francisco T, Olcoz Goñi J, González Herraez L, Bailador C, et al. Prevalence and predictors of non-alcoholic fatty liver disease (NAFLD) in morbidly obese patients undergoing bariatric surgery. Int J Obes (Lond) 2007:S133.
3. Vernon G, Baranova A, Younossi ZM. Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011;34:274-85.
4. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007;132:2169-80.
5. van der Poorten D, Milner KL, Hui J, Hodge A, Trenell MI, Kench JG, et al. Visceral fat: A key mediator of steatohepatitis in metabolic liver disease. Hepatology 2008;48:449-57.
6. Jakobsen MU, Berentzen T, Sorensen TI, Overvad K. Abdominal obesity and fatty liver. Epidemiologic Reviews 2007;29:77-87.
7. Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M, et al. Visceral Adiposity Index: A reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 2010;33:920-2.
8. Petta S, Amato M, Cabibi D, Camma C, Di Marco V, Giordano C, et al. Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1. Hepatology 2010;52:1543-52.
9. Petta S, Amato MC, Di Marco V, Camma C, Pizzolanti G, Barcellona MR, et al. Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2011;35:238-47.
10. Vongsuvanh R, George J, McLeod D, van der Poorten D. Visceral adiposity index is not a predictor of liver histology in patients with non-alcoholic fatty liver disease. J Hepatol 2012;57:392-8.
11. Salas-Salvado J, Rubio MA, Barbany M, Moreno B. SEEDO 2007 Consensus for the evaluation of overweight and obesity and the establishment of therapeutic intervention criteria. Med clin (Barc) 2007;128:184-96.
12. Executive summary: Standards of medical care in diabetes-2013. Diabetes Care 2013;36(Supl. 1):S4-10.
13. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
15. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: The smaller the sample, the milder the disease. J Hepatol 2003;39:239-44.
16. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21.
17. Pouliot MC, Despres JP, Lemieux S, Moorjani S, Bouchard C, Tremblay A, et al. Waist circumference and abdominal sagittal diameter: Best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994;73:460-8.
18. Ong JP, Elariny H, Collantes R, Younoszai A, Chandhoke V, Reines HD, et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg 2005;15:310-5.
19. Bugianesi E, Marchesini G, Gentilcore E, Cua IH, Vanni E, Rizzetto M, et al. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis. Hepatology 2006;44:1648-55.
20. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009;51:371-9.
21. Amato MC, Giordano C. Clinical indications and proper use of Visceral Adiposity Index. Nutrition, metabolism, and cardiovascular diseases: NMCD 2013;23:e312.